Henry F. (Chip) Chambers, M.D.

Co-Editor

• Professor of Medicine, University of California San Francisco (1992-2018)
• Professor of Medicine, Emeritus, University of California San Francisco (2018-Present)
• Chief of Infectious Diseases, San Francisco General Hospital (1992-2013)
• Director, UCSF Infectious Diseases Fellowship Training Program (2002-2013)
• Director, Clinical Research Services, Clinical & Translational Science Institute (2013-2020)
• Editor, American Society for Microbiology’s Antimicrobial Agents and Chemotherapy (2011-2018)

Area of Special Interest

• Antimicrobial drug resistance, staphylococcal infections, experimental therapeutics and epidemiology and pathogenesis of disease caused by Staphylococcus aureus.

Professional Recognitions & Appointments

• Co-Chair, IDSA guidelines committee for treatment of MRSA
• Fellow of the IDSA
• Fellow American College of Physicians
• Elected member of the American Society for Clinical Investigation
• Elected member of the Association of American Physicians

Publication Highlights

Over 300 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases including:

• Prosthetic Valve Endocarditis Diagnosis and Management-New Paradigm Shift Narratives. Clinical Infectious Diseases - May 2021
• Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Journal of Antimicrobial Chemotherapy - September 2020
• Native-Valve Infective Endocarditis. The New England Journal of Medicine - August 2020
• Omadacycline-The Newest Tetracycline. The New England Journal of Medicine - February 2019
• Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clinical Infectious Diseases - March 2018
• A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. New England Journal of Medicine - June 2017
• Antimicrobial Stewardship Approaches in the Intensive Care Unit. Infectious Disease Clinics of North America - September 2017
• New Societal Approaches to Empowering Antibiotic Stewardship. JAMA – March 2016
• Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. PLoS One – February 2016
• Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clinical Infectious Diseases - January 2016
• Antibacterial Treatment for Uncomplicated Skin Infections. New England Journal of Medicine – June 2015

Education

• Centre College Kentucky (BA)
• Vanderbilt University (Medical School)
• University of California San Francisco, School of Medicine (Residency)
• University of California San Francisco, School of Medicine (Infectious Diseases Fellowship)
• Microbiology laboratory of Alexander Tomasz, Rockefeller University (Post-doctoral Fellowship)

Disclosures

• Moderna - Stock
• Merck - Stock, Member of Data Safety Monitoring Board
• Lilly - Medical Expert